Skip Navigation


JAC Advance Access originally published online on January 31, 2008
Journal of Antimicrobial Chemotherapy 2008 61(3):751-753; doi:10.1093/jac/dkn004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/3/751    most recent
dkn004v2
dkn004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Davies, T. A.
Right arrow Articles by Flamm, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, T. A.
Right arrow Articles by Flamm, R. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Activity of doripenem and comparator β-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x

Todd A. Davies*, Wenchi Shang, Karen Bush and Robert K. Flamm

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ, USA

* Corresponding author. Tel: +1-908-707-3465; Fax: +1-908-707-3501; E-mail: tdavies@prdus.jnj.com

Keywords: carbapenems , PBPs , binding affinity

The first 10% of the full text of this article appears below.

Sir,

Doripenem, a parenteral carbapenem, was recently approved in the USA for the treatment of complicated intraabdominal infections (cIAIs) and complicated urinary tract infections (cUTIs) including pyelonephritis. In Europe, a marketing authorization application has been filed for the treatment of cIAIs, cUTIs and nosocomial pneumonia. Doripenem has a broad spectrum of activity against clinically important pathogens including Enterobacteriaceae, Gram-negative non-fermenters, anaerobes and many Gram-positive cocci such as methicillin-susceptible Staphylococcus spp., group A streptococci and pneumococci.1

β-Lactam resistance in Streptococcus pneumoniae is caused by mutations in the penicillin-binding domains . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. Yamada, T. Watanabe, N. Baba, Y. Takeuchi, F. Ohsawa, and S. Gomi
Crystal Structures of Biapenem and Tebipenem Complexed with Penicillin-Binding Proteins 2X and 1A from Streptococcus pneumoniae
Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2053 - 2060.
[Abstract] [Full Text] [PDF]